Clinical Trial Update: Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fludarabine phosphate, melphalan, and low-dose total-body irradiation followed by donor peripheral blood stem cell transplant in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoid and Myeloid Malignancies
• Myelogenous Leukemia

Drugs mentioned

• Donor Peripheral Blood Stem Cells
• Fludarabine phosphate (Fludarabine phosphate)
• Melphalan (Melphalan)
• Total-Body Irradiation (low-dose) (total-body irradiation)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02